Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Luisa Perdigoto

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Frontiers in Oncology|March 30, 2022
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary FunctionShlomit Jessel, Sarah A Weiss, Matthew Austin, et al.
Journal for Immunotherapy of Cancer|March 10, 2023
Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitorsJasmine I Caulfield, Lilach Aizenbud, Ana Luisa Perdigoto, et al.
Diabetes|June 26, 2018
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint InhibitorsAngeliki M Stamatouli, Zoe Quandt, Ana Luisa Perdigoto, et al.
Diabetologia|December 21, 2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosisAna Luisa Perdigoto, Paula Preston-Hurlburt, Pamela Clark, et al.
Journal of the Endocrine Society|March 2, 2023
Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced HypophysitisZoe Quandt, Stephanie Kim, Javier Villanueva-Meyer, et al.
Journal for Immunotherapy of Cancer|September 11, 2025
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetesLilach Aizenbud, Noam Savion Gaiger, Ana Luisa Perdigoto, et al.
The Journal of Clinical Investigation|September 30, 2025
CTLA-4 blockade shifts the B cell repertoire toward autoimmunityElif Çakan, Meng Wang, Yile Dai, et al.
JCI Insight|August 4, 2022
Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetesAna Luisa Perdigoto, Songyan Deng, Katherine C Du, et al.
Journal for Immunotherapy of Cancer|August 14, 2025
Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreasZoe Quandt, Arabella Young, Graham Larson Barlow, et al.
Journal for Immunotherapy of Cancer|October 15, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitorsLing Zhu, Yee-Ming M Cheung, Cherie Chiang, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Frontiers in Oncology|March 30, 2022
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary FunctionShlomit Jessel, Sarah A Weiss, Matthew Austin, et al.
Journal for Immunotherapy of Cancer|March 10, 2023
Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitorsJasmine I Caulfield, Lilach Aizenbud, Ana Luisa Perdigoto, et al.
Diabetes|June 26, 2018
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint InhibitorsAngeliki M Stamatouli, Zoe Quandt, Ana Luisa Perdigoto, et al.
Diabetologia|December 21, 2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosisAna Luisa Perdigoto, Paula Preston-Hurlburt, Pamela Clark, et al.
Journal of the Endocrine Society|March 2, 2023
Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced HypophysitisZoe Quandt, Stephanie Kim, Javier Villanueva-Meyer, et al.
Journal for Immunotherapy of Cancer|September 11, 2025
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetesLilach Aizenbud, Noam Savion Gaiger, Ana Luisa Perdigoto, et al.
The Journal of Clinical Investigation|September 30, 2025
CTLA-4 blockade shifts the B cell repertoire toward autoimmunityElif Çakan, Meng Wang, Yile Dai, et al.
JCI Insight|August 4, 2022
Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetesAna Luisa Perdigoto, Songyan Deng, Katherine C Du, et al.
Journal for Immunotherapy of Cancer|August 14, 2025
Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreasZoe Quandt, Arabella Young, Graham Larson Barlow, et al.
Journal for Immunotherapy of Cancer|October 15, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitorsLing Zhu, Yee-Ming M Cheung, Cherie Chiang, et al.
Pageof 3